

**Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)**  
**[PAR-21-341](#)**  
**Frequently Asked Questions (FAQ)**

The Funding Opportunity Announcement (FOA) [PAR-19-309](#): Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) expires on September 8, 2022, and will not be renewed. This FOA will be replaced by [PAR-21-341](#): Exploratory Grants in Cancer Control (R21 Clinical Trial Optional).

**Q1: What are the behavioral research areas for PAR-21-341?**

A1: The FOA encourages development of innovative psychosocial and behavioral interventions that improve cancer-related health behaviors across the cancer control continuum.

**Q2: When is the first receipt date for PAR-21-341?**

A2: The first receipt date for the behavioral-focused applications is October 7, 2022.

**Q3: Does PAR-21-341 require pilot data?**

A3: PAR-21-341 is an R21 mechanism that provides behavioral research opportunities for early-stage investigators and does not require pilot data.

**Q4: What happens to a prior application submitted to PAR-19-309 that was not funded?**

A4: Applications submitted in response to PAR-19-309 will not be automatically considered in response to the new FOA PAR-21-341. Please be sure to resubmit a new application to be considered for funding under this FOA.

**Q5: Will the study section that reviewed applications in response to PAR-19-309 also review applications in response to PAR-21-341?**

A5: There are no guarantees that the previous study section will review applications in response to the new FOA.

**Q6: Can Foreign Institutions apply for funding?**

A6: Yes, non-domestic entities are eligible to apply for funding. Also, foreign components (performance of any significant scientific element or segment of the project) are allowed.